Last updated: March 2026
TB-500 is a synthetic fragment of thymosin beta-4 — a naturally occurring 43-amino acid peptide found in all human cells — studied across 544+ preclinical publications for tissue repair, wound healing, and anti-inflammatory effects. No completed human clinical trials exist for this specific fragment; only one company ever pursued human trials with thymosin beta-4, and only for eye drops.
Thymosin beta-4 is a multifunctional peptide that operates through several distinct biological pathways — all observed in preclinical models.
Binds monomeric G-actin to regulate cytoskeletal dynamics. This promotes cell migration — a critical step in wound healing and tissue repair. Tβ4 is the primary actin-sequestering peptide in mammalian cells.
Downregulates NF-κB signaling pathway, reducing production of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6. Observed across multiple tissue models including cardiac, dermal, and corneal tissue.
Promotes formation of new blood vessels in damaged tissue. Stimulates endothelial cell migration and tube formation — essential for delivering nutrients and oxygen to healing wounds.
Mobilizes cardiac and tissue progenitor cells via the Akt/PKB survival pathway. Activates integrin-linked kinase (ILK) to promote cell survival and migration in damaged heart tissue.
The most-cited results from preclinical research. Important: these are all animal or in-vitro studies unless specifically noted.
All progress bars below represent animal study data. Results in mice and rats do not reliably predict human outcomes. These numbers show preclinical promise — not proven human efficacy.
544+ studies sounds impressive. But when you look at what actually involved humans, the picture changes dramatically.
Two of the most popular research peptides for healing — different mechanisms, different strengths, often stacked together.
The "stack" is popular but unproven. Many in the peptide research community combine TB-500 and BPC-157. The rationale: complementary mechanisms (systemic + local). The evidence: zero human randomized controlled trials on the combination. It's theory, not science — yet.
What animal studies show — and what the community reports anecdotally. These are very different categories of evidence.
The cancer question: Thymosin beta-4 is upregulated in some cancer tissues. This has raised theoretical concerns. However, no causal evidence has been established — Tβ4 upregulation may be a response to tissue damage rather than a cause of abnormal growth. This remains an open question in the literature.
Beyond musculoskeletal healing, thymosin beta-4 research has explored cardiovascular, neurological, and ophthalmic applications.
Tβ4 promotes wound healing with notably reduced scar tissue formation. Research shows it enhances collagen deposition while simultaneously reducing adhesions and fibrous bands — leading to more functional, less restricted healing compared to untreated wounds.
Animal studies demonstrate Tβ4's ability to promote regeneration of damaged cardiac tissue following myocardial infarction (heart attack). The Bock-Marquette 2004 study showed 50% scar reduction in mouse MI models — potentially through stem cell mobilization and anti-inflammatory pathways.
Preclinical studies have explored Tβ4 for traumatic brain injury (TBI) and spinal cord injury recovery. The peptide appears to support neuronal survival and may promote remyelination — though human data remains absent.
RegeneRx's RGN-259 — a topical ophthalmic formulation of Tβ4 — reached Phase 2/3 clinical trials for dry eye syndrome. This represents the only human clinical trial program for thymosin beta-4, showing the peptide's potential for corneal wound healing.
Cancer Concern Context: Elevated Tβ4 levels have been observed in certain cancer tissues, raising safety questions. However, current evidence suggests this is likely an immune response to tissue damage rather than tumor promotion. When tissue is damaged — whether by injury, inflammation, or cancer — the body upregulates healing factors like Tβ4. Correlation is not causation, but this remains an active research area.
TB-500 is not approved for human use anywhere in the world. Here's the full regulatory picture.
Not approved for human use. Investigational only. RegeneRx held an IND for ophthalmic Tβ4 (RGN-259) but no drug has been approved.
Investigational OnlyBanned by the World Anti-Doping Agency since 2011. Listed under S2 — Peptide Hormones, Growth Factors. Prohibited at all times, in and out of competition.
Banned Since 2011Banned in multiple jurisdictions. Several racehorses have tested positive for TB-500, leading to disqualifications and trainer suspensions.
Banned SubstanceAvailable from peptide suppliers labeled "for research use only." Not intended for human consumption. Quality and purity vary by supplier.
Research Use OnlyThe primary research behind the data on this page. Click PMID links to read the full papers on PubMed.
Fragment vs Full Peptide
TB-500 is a synthetic fragment — specifically the active region (amino acids 17-23) of the full 43-amino-acid thymosin beta-4 protein. This distinction matters more than most peptide guides acknowledge, and it's increasingly discussed among practitioners who work with both forms.
| Property | TB-500 (Fragment) | Full TB4 |
|---|---|---|
| Structure | Active region (aa 17-23) | Complete 43 amino acids |
| Actin Binding / Cell Migration | ✅ Primary mechanism | ✅ Included + additional domains |
| Angiogenesis | Partial | Full cascade |
| Inflammation Modulation | Moderate | Broader pathway coverage |
| Tissue Remodeling | Limited evidence | Collagen deposition + reduced scarring |
| Cardioprotection | Not demonstrated | Cardiac regeneration post-MI |
| Clinical Trials | Preclinical only | Phase 2 (dry eye, RegeneRx) |
| Availability | Widely available (research) | Less common, higher cost |
The most advanced clinical work has been done with full TB4, not the fragment:
TB-500 works. The preclinical evidence for the fragment's role in cell migration and tissue repair is solid. For many applications — particularly acute soft tissue injuries — the fragment delivers meaningful results and is more accessible.
Full TB4 may work better for complex or stubborn injuries. When you need the complete biological cascade — angiogenesis, anti-inflammatory modulation, tissue remodeling, and reduced scarring all working together — the full peptide engages more pathways. Practitioners who've used both frequently report that full TB4 produces deeper, more sustained healing responses, particularly in chronic injuries and when stacked with BPC-157 or GHK-Cu.
The tradeoff is availability and cost. Full TB4 is harder to source, more expensive, and less commonly carried by research suppliers. TB-500 remains the practical choice for most people, with the understanding that it's delivering a targeted signal rather than the complete one.
Self-Assessment
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
⚕️ Always consult a healthcare provider before starting any peptide protocol.
An honest assessment of where TB-500 research stands. The "don't know" column is intentionally longer.
This page is for educational and informational purposes only. It is not medical advice, and nothing here should be interpreted as a recommendation to use TB-500 or any peptide. TB-500 (Thymosin Beta-4) is NOT approved by the FDA for human use. It is a research compound available only for laboratory and investigational purposes. The studies cited are overwhelmingly preclinical (animal and in-vitro). Always consult a qualified healthcare provider before making any decisions about your health. MeetPeptide does not sell peptides or endorse their use outside of legitimate research settings.
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.